CASE CONCLUSION
After treatment with bortezomib the patient
is well for 9 months. Subsequently, however,
he develops increasing lymphadenopathy and
progressive fatigue. He is then started on lenalidomide 25 mg orally daily for 21 out of 28
days. He experiences significant fatigue with lenalidomide and prolonged neutropenia requiring dose delays, despite dose modification to
10 mg orally daily. He requires discontinuation
of lenalidomide. Given persistent disease, the
patient then begins treatment with ibrutinib.
Within a few days of starting ibrutinib therapy,
he experiences a marked but transient leukocytosis. Two months later, the patient’s palpable
lymphadenopathy has decreased, and his anemia and thrombocytopenia related to MCL are
improving. He has tolerated treatment well. His
course has been complicated only by a mild,
pruritic maculopapular eruption on his chest,
back, and arms, that was responsive to topical
low-dose steroids. He remains on ibrutinib 1
year later.
CONCLUSION
Advances in our understanding of MCL treatment are revolutionizing the approach to this
once deadly disease. Over the next several years,
these gains will weave themselves into the current treatment paradigm and likely alter the
treatment landscape for MCL as we know it.
REFERENCES
1. Armitage JO, Weisenburger DD. New approach to classifying
non-Hodgkin’s lymphomas: clinical features of the major
histologic subtypes. Non-Hodgkin’s Lymphoma Classification
Project. J Clin Oncol 1998;16:2780–95.
2. Zhou Y, Wang H, Fang W, et al. Incidence trends of mantle
cell lymphoma in the United States between 1992 and 2004.
Cancer 2008;113:791–8.
3. Geisler CH. Front-line treatment of mantle cell lymphoma.
Haematologica 2010;95:1241–3.
4. Fernandez V, Salamero O, Espinet B, et al. Genomic and
gene expression profiling defines indolent forms of mantle
cell lymphoma. Cancer Res 2010;70:1408–18.
5. Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol
2009;27:1209–13.
6. Bertoni F, Ponzoni M. The cellular origin of mantle cell lymphoma. Int J Biochem Cell Biol 2007;39:1747–53.
7. de Boer CJ, van Krieken JH, Kluin-Nelemans HC, et al. Cyclin
D1 messenger RNA overexpression as a marker for mantle
cell lymphoma. Oncogene 1995;10:1833–40.
8. Jares P, Colomer D, Campo E. Molecular pathogenesis of
mantle cell lymphoma. J Clin Invest 2012;122:3416–23.
9. Rosenwald A, Wright G, Wiestner A, et al. The proliferation
gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma.
Cancer Cell 2003;3:185–97.
10. Determann O, Hoster E, Ott G, et al. Ki-67 predicts outcome
in advanced-stage mantle cell lymphoma patients treated with
anti-CD20 immunochemotherapy: results from randomized
trials of the European MCL Network and the German Low
Grade Lymphoma Study Group. Blood 2008;111:2385–7.
11. Vegliante MC, Palomero J, Perez-Galan P, et al. SOX11
regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood
2013;121:2175–85.
12. Bea S, Valdes-Mas R, Navarro A, et al. Landscape of somatic
mutations and clonal evolution in mantle cell lymphoma.
Proc Natl Acad Sci U S A 2013;110:18250– 5.
13. Zelenetz AD, Abramson JS, Advani RH, et al. Non- Hodgkin’s
lymphomas. J Natl Compr Canc Netw 2011;9: 484–560.
14. Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment
of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014;32:3059–68.
15. Zelenetz AD, Abramson JS, Advani RH, et al. NCCN Clinical
Practice Guidelines in Oncology: non-Hodgkin’s lymphomas.
J Natl Compr Canc Netw 2010;8:288–334.
16. Hoster E, Dreyling M, Klapper W, et al. A new prognostic
index (MIPI) for patients with advanced-stage mantle cell
lymphoma. Blood 2008;111:558–65.
17. Geisler CH, Kolstad A, Laurell A, et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior
to the International Prognostic Index (IPI) in predicting
survival following intensive first-line immunochemotherapy
and autologous stem cell transplantation (ASCT). Blood
2010;115:1530–3.
18. Tiemann M, Schrader C, Klapper W, et al. Histopathology,
cell proliferation indices and clinical outcome in 304 patients
with mantle cell lymphoma (MCL): a clinicopathological
study from the European MCL Network. Br J Haematol
2005;131: 29–38.
19. Raty R, Franssila K, Joensuu H, et al. Ki-67 expression level,
histological subtype, and the International Prognostic Index
as outcome predictors in mantle cell lymphoma. Eur J Haematol 2002;69: 11–20.
20. Vogt N, Klapper W. Variability in morphology and cell proliferation in sequential biopsies of mantle cell lymphoma at
BOARD REVIEW QUESTIONS
Test your knowledge of this topic. Go to
www.turner-white.com/brm/bonco.htm and
click the Board Review Questions button.
